Phaseline

Targets › USH2A

USH2A (Usherin): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Ophthalmology; next expected readout Jul 2028.

Involved in hearing and vision as member of the USH2 complex. In the inner ear, required for the maintenance of the hair bundle ankle formation, which connects growing stereocilia in developing cochlear hair cells. (UniProt, O75445)

Open in Phaseline: the race on USH2A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Laboratoires TheaUltevursen
USH2A exon 13 gene therapy
USH2APhase 2Retinitis Pigmentosa (RP)Jul 2028

Conditions

Retinitis Pigmentosa (RP) (1)

Modalities

other (1)

Companies

Laboratoires Thea (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.